Navigation Links
Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries
Date:1/9/2008

o.aidstechtransfer@roche.com.

Interested local manufacturers in the following countries are invited to contact Roche to discuss the Technology Transfer Initiative: Afghanistan, Angola, Bangladesh, Benin, Bhutan, Burkina Faso, Botswana, Burundi, Cambodia, Cameroon, Congo, Cote d'Ivoire, Cape Verde, Central African Republic, Chad Comoros, Democratic Republic of Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Gambia, Guinea, Guinea-Bissau, Haiti, Kenya, Kiribati, Lao People's Democratic Republic, Lesotho, Liberia, Madagascar, Malawi, Maldives, Mali, Mauritius, Mauritania, Mozambique, Myanmar, Namibia, Nigeria, Nepal, Niger, Rwanda, Samoa, Sao Tome and Principe, Seychelles, Senegal, Sierra Leone, Solomon Islands, Somalia, South Africa, Swaziland, United Republic of Tanzania, Timor-Leste, Togo, Tuvalu, Uganda, Vanuatu, Yemen, Zambia, Zimbabwe.

About Roche's patent and pricing policy

In addition to its Technology Transfer Initiative, Roche will maintain its current pricing and patent policy. No patents for any of Roche medicines - across all disease areas - will be filed in the world's Least Developed Countries (LDCs), as defined by the UN. Roche will not file patents on new antiretroviral medicines in LDCs or sub-Saharan Africa. Roche will not take action in these countries against the sale or manufacture of generic versions of antiretroviral medicines. Generic versions of such HIV medicines can therefore be produced in LDCs and sub-Saharan Africa without the need for a voluntary or compulsory license. Roche makes its HIV protease inhibitors Invirase and Viracept available at no-profit prices for direct supplies from Roche Basel to LDCs and sub-Saharan Africa.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more tha
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurochem to present at JPMorgan Healthcare Conference
2. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
3. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
4. David Luci Joins MacroChem as General Counsel and Vice President Corporate Development
5. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
6. Rochester Medical Reports Record Fourth Quarter Sales and Record Year
7. Roche Confirms Commencement of Due Diligence with Ventana
8. Neurochem reports results for third quarter of fiscal 2007
9. Roche Offers Innovative Website Designed to Empower Cancer Patients
10. Roche Extends Tender Offer for Ventana
11. Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2010)... Reporter , , THURSDAY, Sept. 2 (HealthDay News) -- ... Boniva (ibandronate), Fosamax (alendronate) or Actonel (risedronate) to ... risk of esophageal cancer, British researchers report. ... the most commonly used drugs to treat osteoporosis ... suggested that they may increase the risk of ...
(Date:9/3/2010)... , , THURSDAY, Sept. 2 (HealthDay News) -- Many Americans ... often believing they are thinner than they really are, ... poll finds. As part of the Harris Interactive/HealthDay ... weight, from which pollsters calculated their body-mass index (BMI), ... asked which category of weight they thought they fell ...
(Date:9/2/2010)... HealthDay Reporter , , THURSDAY, Sept. 2 (HealthDay ... in less than two hours, making only one doctor ... a potentially significant advance against a disease that kills ... developing countries. "This is a very important discovery," ... professor of medicine at New York University. "This could ...
(Date:9/2/2010)... of mistaken identity that may have a significant impact ... study, published by Cell Press in the September 3rd ... suggests that despite their "stem cell-like" characteristics, most aggressive ... stem cells. , The glandular tissue of the breast ... inner "luminal" cells. The basal layer consists mostly of ...
(Date:9/2/2010)... that have left millions homeless and hungry to the ... way in many parts of the world where disasters ... Sahel region, severe drought has been followed by floods ... of people among the world,s poorest. More than half ... as well as millions more in neighbouring Chad, Mali ...
Breaking Medicine News(10 mins):Health News:Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer 2Health News:Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer 3Health News:Many Americans Don't Even Know They're Fat 2Health News:Many Americans Don't Even Know They're Fat 3Health News:Experimental TB Test Called Fast and Accurate 2Health News:Experimental TB Test Called Fast and Accurate 3Health News:'Basal-like' breast cancer does not originate from basal stem cells 2Health News:Water management and malnutrition crucial issues at McGill food conference 2
... Encourages Women to ,Speak Up For Down There, During National ... ... Despite living in a society,that promotes images and icons of ... Dr. Sue Johannsen and even,former Supreme Court Justice Sandra Day O,Conner, ...
... May 13, 2008 The American ... infection control guidelines regarding gastrointestinal (GI) endoscopy. The ... rare event since the adoption of endoscope reprocessing ... in the May issue of GIE: Gastrointestinal Endoscopy, ...
... Fla., May 13 The rate of childhood,obesity ... and, in Florida,32.5 percent of children ages 10 ... serious and widespread threat of the obesity epidemic ... The Blue,Foundation for a Healthy Florida ( http://www.bluefoundationfl.com ...
... to host collegiate and professional competitions airing ... nationally on ESPN2 and ESPNU, ... a two-year agreement as title sponsor of the Aflac Outdoor Games.,The ... at the,South Commons Softball Complex in Columbus, GA. Aflac Outdoor Games ...
... expression of a key enzyme, vitamin D protects healthy ... lead to cancer, University of Rochester Medical Center researchers ... properties of vitamin D, said Yi-Fen Lee, associate professor ... research. Our findings reflect what we see in those ...
... Acid and Clindamycin Products Developed with Invisicare(R), ... Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), ... enhanced patented dermatology,products, announced it has signed ... Ltd. ("Embil"). The Agreement is for the ...
Other Medicine News:Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 2Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 3Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 4Health News:ASGE issues updated infection control guidelines for gastrointestinal endoscopy 2Health News:ASGE issues updated infection control guidelines for gastrointestinal endoscopy 3Health News:The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity 2Health News:Aflac Announces Title Sponsorship of Outdoor Games 2Health News:Aflac Announces Title Sponsorship of Outdoor Games 3Health News:Vitamin D protects cells from stress that can lead to cancer 2Health News:Skinvisible Signs Licensing Agreement for Two Acne Formulations 2Health News:Skinvisible Signs Licensing Agreement for Two Acne Formulations 3
(Date:9/2/2010)... SHANGHAI, Sept. 3 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
(Date:9/2/2010)... 2 Neuronetics, Inc., maker of the ... been selected by the World Economic Forum as ... process, the World Economic Forum,s Technology Pioneers program ... and apply the most innovative and transformational technologies ... impact on the future of business and society. ...
(Date:9/2/2010)... The SCOOTER Store, the nation,s largest ... announced the creation of a new internal division ... services to complement its traditional power mobility business. ... will be based in New Braunfels, Texas, and ... The SCOOTER Store. It will leverage the company,s ...
Breaking Medicine Technology:Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification 2Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification 3Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification 4Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification 5Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification 6Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification 7Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer 2Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer 3The SCOOTER Store Creates Home Care Equipment Division 2The SCOOTER Store Creates Home Care Equipment Division 3Celsion Receives SBIR Grant To Expand Its Technology Platform 10586 1Celsion Receives SBIR Grant To Expand Its Technology Platform 10586 2Celsion Receives SBIR Grant To Expand Its Technology Platform 10586 3Edible nanostructures 75572 1Edible nanostructures 75572 2Edible nanostructures 75572 3University at Buffalo symposium on in silico methods high throughput screening 15201 1University at Buffalo symposium on in silico methods high throughput screening 15201 2University at Buffalo symposium on in silico methods high throughput screening 15201 3
... 3 Anesiva,Inc. (Nasdaq: ANSV ) today ... has approved Anesiva,s investigational new drug application,for Adlea(TM), ... Phase 3 clinical development for the management of ... a Phase 2 clinical,trial of Adlea in patients ...
... also Meets Primary Endpoint (p ... III Study, Pharmacokinetic ... Occurring at a 0.33% Rate per XIAFLEX injection, Conference call scheduled ... 3 Auxilium,Pharmaceuticals, Inc. (Nasdaq: AUXL ) today announced positive top-line,efficacy and ...
Other Medicine Technology:Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application 2Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application 3Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11
... Codman Sofwire Cable System, ... fixation including sublaminar interspinous ... facial surgery, sternotomy closure. ... and a complete set ...
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
... Inductive demineralized bone matrix and ... cancellous chips will be free ... matrix particle size is 125 ... particle size is 1 - ...
Demineralized Freeze-dried Bone Allograft (DFDBA) processed from cortical bone. Demineralized cortical powder is free of all soft tissue....
Medicine Products: